Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.2.u1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2024
Jul. 31, 2023
Jul. 31, 2024
Jul. 31, 2023
Oct. 31, 2023
Segment Reporting Information [Line Items]          
Net income/(loss) $ (3,315) $ (2,548) $ (9,785) $ (7,209)  
Total operating costs and expenses 3,592 2,844 10,668 8,170  
Less non-cash stock-based compensation (1,179) (1,217) (3,699) (3,507)  
Operating costs and expenses excluding non-cash stock-based compensation 2,413 1,627 6,969 4,663  
Total assets 22,908   22,908   $ 25,522
CAR-T Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net income/(loss) (1,145) (1,091) (4,115) (2,999)  
Operating costs and expenses excluding non-cash stock-based compensation 789 713 2,943 1,930  
Total assets 7,493   7,493   7,523
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net income/(loss) (2,160) (1,390) (5,628) (3,261)  
Operating costs and expenses excluding non-cash stock-based compensation 1,614 855 3,988 1,966  
Total assets 15,290   15,290   17,215
Other [Member]          
Segment Reporting Information [Line Items]          
Net income/(loss) (10) (67) (42) (949)  
Operating costs and expenses excluding non-cash stock-based compensation 10 $ 59 38 $ 767  
Total assets $ 125   $ 125   $ 784